Semantic search

This page or action requires JavaScript to work. Please enable JavaScript in your browser or use a browser where it is supported, so that functionality can be provided as requested. For further assistance, please have a look at the noscript help page.

Search Clear all entries

	Outcome specification	Results during intervention	Overall RoB judgment
Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial	Weight fluctuations, total days without feeding tube or gastrostomy	Over the course of the intervention and after: no difference for weight fluctuations (p=0.1454) or need for a feeding tube (no p-value) between arms.	some concerns
Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial	Appetite with questionnaire (no further information)	Over the course of the intervention and after: no difference (p=0.3295) between arms	some concerns
Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies	Change in NRS value for average pain	No differences between arms after 5 weeks (no p-value)	some concerns
Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies	Specification NRS: constipation NRS	Results: Higher change in SGIC for global impression and better change assessed by physician in 'general functional ability' of Sativex arm compared to placebo arm Scores in SGIC better in Sativex arm at week 3 (p = 0.041), 5 (p = 0.022) and last visit (p = 0.022) PGIC better at week 5 (p=0.037) compared to placebo arm	some concerns
Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies	Change in NRS value for the worst pain	No differences between arms after 5 weeks (no p-value).	some concerns

Query log